Q1 Earnings Forecast for Immunic Issued By HC Wainwright

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Immunic in a research note issued to investors on Tuesday, April 15th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings per share of ($0.26) for the quarter. HC Wainwright currently has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunic's Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS and Q4 2025 earnings at ($0.18) EPS.

Other research analysts also recently issued reports about the stock. StockNews.com downgraded shares of Immunic from a "hold" rating to a "sell" rating in a report on Thursday, March 20th. William Blair started coverage on Immunic in a research report on Tuesday, March 25th. They issued an "outperform" rating for the company. D. Boral Capital restated a "buy" rating and set a $17.00 price target on shares of Immunic in a report on Thursday, April 10th. Finally, B. Riley reiterated a "buy" rating and issued a $6.00 price objective on shares of Immunic in a report on Wednesday. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Immunic currently has a consensus rating of "Buy" and a consensus target price of $13.20.

Immunic Trading Up 4.0 %

NASDAQ IMUX traded up $0.04 during trading on Wednesday, hitting $0.98. 215,076 shares of the company's stock were exchanged, compared to its average volume of 624,931. The stock's 50 day moving average price is $1.08 and its two-hundred day moving average price is $1.14. The company has a market cap of $93.90 million, a PE ratio of -0.80 and a beta of 1.91. Immunic has a fifty-two week low of $0.83 and a fifty-two week high of $2.11.

Institutional Trading of Immunic

Several institutional investors have recently added to or reduced their stakes in IMUX. Millennium Management LLC lifted its position in shares of Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company's stock worth $580,000 after purchasing an additional 479,846 shares during the period. Renaissance Technologies LLC lifted its holdings in Immunic by 45.6% in the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock valued at $567,000 after buying an additional 177,542 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Immunic by 90.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock valued at $205,000 after buying an additional 96,894 shares during the period. Barclays PLC bought a new stake in Immunic during the fourth quarter valued at $84,000. Finally, HB Wealth Management LLC acquired a new stake in Immunic during the 4th quarter worth about $81,000. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.